Terlipressin Evidence Guide
Terlipressin (Terlivaz) is FDA-approved for hepatorenal syndrome type 1 - a life-threatening complication of advanced cirrhosis - with Phase 3 data from the CONFIRM trial showing significant reversal of HRS-1 versus placebo. As the first FDA-approved treatment specifically for HRS-1, it represents a meaningful regulatory milestone. Respiratory failure risk in high MELD patients is a real safety consideration that limits its use.
Our Take
Terlipressin (Terlivaz) is FDA-approved for hepatorenal syndrome type 1 - a life-threatening complication of advanced cirrhosis - with Phase 3 data from the CONFIRM trial showing significant reversal of HRS-1 versus placebo. As the first FDA-approved treatment specifically for HRS-1, it represents a meaningful regulatory milestone. Respiratory failure risk in high MELD patients is a real safety consideration that limits its use.
- Evidence context
- Hepatorenal syndrome type 1 (HRS-1), vasopressin V1 receptor agonism, portal hypertension research
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 1mg IV every 6 hours (HRS-1), titrated based on response and serum creatinine
Benefits and Evidence
- Hepatorenal Syndrome Reversal: Level A, includes human evidence - CONFIRM trial showed significantly higher rate of verified HRS reversal with terlipressin vs placebo (32% vs 17%). Reduces serum creatinine and improves renal function in HRS-1.
- Variceal Bleeding Control: Level A, includes human evidence - Effective for acute control of esophageal variceal hemorrhage. Comparable efficacy to somatostatin analogs with the advantage of bolus dosing.
- Ischemic Complications: Level A, includes human evidence - Vasoconstriction-related ischemic events (cardiac, digital, mesenteric, skin necrosis) reported. Respiratory failure also reported in CONFIRM trial at higher rates than placebo.
Side Effects and Warnings
- Abdominal pain and cramping
- Diarrhea
- Respiratory failure
- Skin necrosis and peripheral ischemia
- Bradycardia
- Hyponatremia
- Serious ischemic events (coronary, peripheral, mesenteric) - contraindicated in significant coronary, peripheral, or mesenteric vascular disease
- Respiratory failure - monitor oxygenation; increased risk in patients with volume overload
Research Dosage References
- <strong>Intravenous injection</strong> - 0.85 mg - Every 6 hours - For hepatorenal syndrome (Terlivaz). May increase to 1.7 mg every 6 hours if serum creatinine has not decreased by >=30% by day 4. Maximum treatment duration: 14 days.
- <strong>Intravenous bolus</strong> - 1-2 mg - Every 4-6 hours - For acute variceal hemorrhage (outside US). Given as slow IV bolus. Duration typically 2-5 days.
Mechanism of Action
Terlipressin acts as a prodrug vasopressin analog with V1a receptor selectivity: 1. Prodrug activation: Triglycyl residues are cleaved by tissue peptidases, slowly releasing active lysine-vasopressin, providing a prolonged duration of action. 2. V1a-preferential vasoconstriction: Causes splanchnic arterial vasoconstriction, reducing portal pressure and redirecting blood flow from the overexpanded splanchnic circulation to the systemic and renal circulations. 3. Renal perfusion improvement: In hepatorenal syndrome, reverses the pathological splanchnic vasodilation and effective arterial underfilling that drives renal vasoconstriction and kidney failure. 4. Portal pressure reduction: Reduces portal venous pressure, making it useful for acute variceal hemorrhage and related complications of portal hypertension.
Legal Status
FDA-approved (September 2022) for hepatorenal syndrome with rapid reduction in kidney function. Marketed as Terlivaz by Mallinckrodt. Used outside the US (as Glypressin) for variceal bleeding for decades.
Primary Sources
- Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome (CONFIRM). N Engl J Med, 2021.
- Terlipressin for hepatorenal syndrome: a systematic review and meta-analysis. Hepatology, 2010.
- Terlipressin versus noradrenaline for hepatorenal syndrome. J Hepatol, 2016.
Quick Answers
Where is the strongest evidence for Terlipressin?
Terlipressin (Terlivaz) is FDA-approved for hepatorenal syndrome type 1 - a life-threatening complication of advanced cirrhosis - with Phase 3 data from the CONFIRM trial showing significant reversal of HRS-1 versus placebo. As the first FDA-approved treatment specifically for HRS-1, it represents a meaningful regulatory milestone. Respiratory failure risk in high MELD patients is a real safety consideration that limits its use. Evidence context: Hepatorenal syndrome type 1 (HRS-1), vasopressin V1 receptor agonism, portal hypertension research.
What are the main side effects of Terlipressin?
Terlipressin side effects and warning signals include Abdominal pain and cramping, Diarrhea, Respiratory failure, Skin necrosis and peripheral ischemia, and Bradycardia.
What evidence level is Terlipressin?
Terlipressin is rated Level A; the listed research status is FDA Approved.